Max Topp
Overview
Explore the profile of Max Topp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lang F, Voss A, Kobbe G, Junghanss C, Beck J, Viardot A, et al.
Leuk Lymphoma
. 2025 Feb;
:1-9.
PMID: 39921529
Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA)...
2.
Fleischer A, Kurth S, Duell J, Topp M, Strunz P, Mersi J, et al.
J Immunother Cancer
. 2025 Jan;
12(12.
PMID: 39794934
Background: Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative modality in the treatment of patients with cancer. However, it is increasingly evident that this therapeutic approach is...
3.
Frenking J, Zhou X, Wagner V, Hielscher T, Kauer J, Mai E, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39379098
Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine...
4.
Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, et al.
Br J Haematol
. 2024 May;
205(3):999-1010.
PMID: 38719214
Biomarkers for cytopenias following CAR T-cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients...
5.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, et al.
Haematologica
. 2024 Feb;
109(12):3892-3903.
PMID: 38356450
The ongoing development of immunotherapies, including chimeric antigen receptor (CAR) T cells, has revolutionized cancer treatment. In pediatric relapsed/refractory B-lineage acute leukemia antiCD19-CAR induce impressive initial response rates, with event-free...
6.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al.
Blood
. 2023 Jun;
142(10):865-877.
PMID: 37300386
Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a...
7.
Topp M, Dlugosz-Danecka M, Skotnicki A, Salogub G, Viardot A, Klein A, et al.
Trials
. 2023 Jan;
24(1):4.
PMID: 36597128
Background: The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the...
8.
Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, et al.
Bone Marrow Transplant
. 2022 Nov;
58(2):229-232.
PMID: 36418916
No abstract available.
9.
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, et al.
Blood
. 2022 Mar;
140(4):349-358.
PMID: 35316325
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German...
10.
Zoellner A, Unterhalt M, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B, et al.
Lancet Haematol
. 2021 Aug;
8(9):e648-e657.
PMID: 34450102
Background: Autologous haematopoietic stem-cell transplantation (HSCT) in first remission is the current standard treatment in fit patients with mantle cell lymphoma. In this long-term follow-up study, we aimed to evaluate...